II期临床-话题@MedSci

#II期临床#

478篇内容 | 2559人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524907, encodeId=9406152490e6d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, objectType=article, longId=204833, objectId=e12e20483351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12e20483351, replyNumber=0, likeNumber=71, createdTime=2020-12-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12e20483351, moduleTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12e20483351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524906, encodeId=6f8a15249061b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局, objectType=article, longId=204745, objectId=8fbc204e4566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fbc204e4566, replyNumber=0, likeNumber=75, createdTime=2020-12-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fbc204e4566, moduleTitle=中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fbc204e4566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524905, encodeId=dcd51524905d3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, objectType=article, longId=204701, objectId=9ebf204e014c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ebf204e014c, replyNumber=0, likeNumber=41, createdTime=2020-12-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ebf204e014c, moduleTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ebf204e014c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524904, encodeId=66f31524904e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, objectType=article, longId=204591, objectId=0d4f2045916e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4f2045916e, replyNumber=0, likeNumber=54, createdTime=2020-12-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4f2045916e, moduleTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4f2045916e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524903, encodeId=58c81524903de, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果, objectType=article, longId=204514, objectId=6550204514fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6550204514fe, replyNumber=0, likeNumber=68, createdTime=2020-12-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6550204514fe, moduleTitle=TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6550204514fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524902, encodeId=a631152490264, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=国内**新冠病毒重组蛋白亚单位疫苗启动III期临床, objectType=article, longId=204110, objectId=3247204110d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3247204110d5, replyNumber=0, likeNumber=78, createdTime=2020-12-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3247204110d5, moduleTitle=国内**新冠病毒重组蛋白亚单位疫苗启动III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3247204110d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524901, encodeId=4a42152490196, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, objectType=article, longId=203861, objectId=324020386153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=324020386153, replyNumber=0, likeNumber=54, createdTime=2020-12-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=324020386153, moduleTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=324020386153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524900, encodeId=669d152490082, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, objectType=article, longId=203849, objectId=7f4820384995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f4820384995, replyNumber=0, likeNumber=63, createdTime=2020-11-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f4820384995, moduleTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f4820384995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524899, encodeId=97701524899b8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, objectType=article, longId=203842, objectId=f57420384247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f57420384247, replyNumber=0, likeNumber=63, createdTime=2020-11-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f57420384247, moduleTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f57420384247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524897, encodeId=5412152489e4f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, objectType=article, longId=203674, objectId=94d42036e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d42036e4b2, replyNumber=0, likeNumber=71, createdTime=2020-11-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d42036e4b2, moduleTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d42036e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524896, encodeId=cf0b1524896b6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%, objectType=article, longId=203553, objectId=aa6a203553c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6a203553c0, replyNumber=0, likeNumber=75, createdTime=2020-11-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6a203553c0, moduleTitle=III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6a203553c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524895, encodeId=194c1524895f0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, objectType=article, longId=203274, objectId=cfcb2032e4c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfcb2032e4c1, replyNumber=0, likeNumber=18, createdTime=2020-11-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfcb2032e4c1, moduleTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfcb2032e4c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524894, encodeId=b2271524894c6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, objectType=article, longId=203254, objectId=0697203254d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0697203254d7, replyNumber=0, likeNumber=58, createdTime=2020-11-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0697203254d7, moduleTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0697203254d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524893, encodeId=bbfc152489352, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, objectType=article, longId=203249, objectId=a99020324958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a99020324958, replyNumber=0, likeNumber=57, createdTime=2020-11-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a99020324958, moduleTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a99020324958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524892, encodeId=65131524892d7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, objectType=article, longId=203246, objectId=d0c62032469d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c62032469d, replyNumber=0, likeNumber=78, createdTime=2020-11-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c62032469d, moduleTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c62032469d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524898, encodeId=3085152489814, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床, objectType=article, longId=203221, objectId=df78203221cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df78203221cf, replyNumber=0, likeNumber=0, createdTime=2020-11-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df78203221cf, moduleTitle=HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df78203221cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524891, encodeId=506e15248917a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据, objectType=article, longId=203078, objectId=c59e2030e858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c59e2030e858, replyNumber=0, likeNumber=74, createdTime=2020-11-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c59e2030e858, moduleTitle=Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c59e2030e858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524890, encodeId=817615248901a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验, objectType=article, longId=203072, objectId=4a132030e2bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a132030e2bd, replyNumber=0, likeNumber=60, createdTime=2020-11-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a132030e2bd, moduleTitle=FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a132030e2bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524889, encodeId=753c152488956, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=中国批准国产阿尔茨海默症早诊示踪剂进入III期临床, objectType=article, longId=202931, objectId=45b2202931e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45b2202931e6, replyNumber=0, likeNumber=142, createdTime=2020-11-06, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45b2202931e6, moduleTitle=中国批准国产阿尔茨海默症早诊示踪剂进入III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45b2202931e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524888, encodeId=1c59152488885, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床, objectType=article, longId=202926, objectId=e79820292602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79820292602, replyNumber=0, likeNumber=67, createdTime=2020-11-06, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79820292602, moduleTitle=诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e79820292602)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究

2020-12-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局

2020-12-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果

2020-12-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床

2020-12-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果

2020-12-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

国内**新冠病毒重组蛋白亚单位疫苗启动III期临床

2020-12-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验

2020-12-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA批准AMZ002治疗婴儿癫痫病的III期临床试验

2020-11-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持

2020-11-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果

2020-11-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%

2020-11-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）

2020-11-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JAHA：二甲双胍治疗肺动脉高压的II期临床试验

2020-11-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停

2020-11-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功

2020-11-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床

2020-11-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据

2020-11-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验

2020-11-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

中国批准国产阿尔茨海默症早诊示踪剂进入III期临床

2020-11-06

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床

2020-11-06

科室
- - 订阅+
  - 更多科室
工具
服务